Search

Crinetics Pharmaceuticals Inc

Закрыт

СекторЗдравоохранение

83.54 -0.12

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

83.36

Макс.

83.72

Ключевые показатели

By Trading Economics

Доход

-5M

-128M

Продажи

6.8M

11M

Прибыль на акцию

-1.23

Рентабельность продаж

-1,191.029

Сотрудники

594

EBITDA

-5M

-127M

Рекомендации

By TipRanks

Рекомендации

Нейтрально

Прогноз на 12 месяцев

+2.44% upside

Дивиденды

By Acuity

Следующий отчет о доходах

4 авг. 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

4.5B

8.9B

Предыдущая цена открытия

83.66

Предыдущая цена закрытия

83.54

Новостные настроения

By Acuity

36%

64%

127 / 340 Рейтинг в Healthcare

Crinetics Pharmaceuticals Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

31 июл. 2026 г., 23:56 UTC

News

Citigroup maintained its Buy rating on Welltower and raised its price target to $275. Shares are modestly higher in after-market trading.

31 июл. 2026 г., 23:56 UTC

News

Citigroup maintained its Buy rating on Neurocrine Biosciences and raised its price target to $249. Shares are higher in after-market trading.

31 июл. 2026 г., 23:51 UTC

Social Media
Correlated Moves
News

Meta Platforms Inc shares are lower in after-market hours, pressured by broader market weakness and concerns over rising AI spending following a disappointing earnings report.

31 июл. 2026 г., 23:46 UTC

News

3M shares declined in after-market trading amid concerns over insider selling by EVP Kevin H. Rhodes, who sold $1.3 million worth of stock.

31 июл. 2026 г., 23:41 UTC

Social Media
News
Correlated Moves

Goldman Sachs shares declined in after-market trading amid broader market turmoil and hedge fund degrossing linked to losses on leveraged AI investments.

31 июл. 2026 г., 23:41 UTC

News

JPMorgan Chase & Co. shares are lower in after-market trading following a note highlighting ongoing market rotation and challenges from rising long-term Treasury yields.

31 июл. 2026 г., 23:36 UTC

News

Carvana shares declined in after-market trading following Citigroup's price target cut to $90, amid broader market weakness from Apple's disappointing guidance.

31 июл. 2026 г., 23:36 UTC

News

DoorDash Inc shares are lower in after-market trading amid concerns over order demand and rising fuel prices ahead of its upcoming Q2 earnings report.

31 июл. 2026 г., 23:36 UTC

News

Warner Bros Discovery shares are lower in after-market trading amid concerns over job losses tied to Paramount's $81 billion acquisition and its extended offer deadlines.

31 июл. 2026 г., 23:36 UTC

News

Bloom Energy Corp shares are lower in after-market trading amid a class action lawsuit alleging securities fraud related to its reliance on Chinese scandium.

31 июл. 2026 г., 23:32 UTC

News

Recursion Pharmaceuticals Inc shares are lower in after-market hours, reflecting broader market trends amid mixed performance among major tech stocks and upcoming economic data.

31 июл. 2026 г., 23:31 UTC

News

KKR & Co Inc reported record Q2 revenue of $6.31 billion, yet shares are trading lower in after-market hours following earlier volatility.

31 июл. 2026 г., 23:26 UTC

News

Norwegian Cruise Line shares are lower in after-market hours following Citigroup's price target cut to $22 amid ongoing valuation concerns.

31 июл. 2026 г., 23:26 UTC

News

NOW Inc shares are higher after market hours, reflecting positive sentiment in the trading companies sector and ongoing demand for energy products.

31 июл. 2026 г., 23:26 UTC

News

Pomerantz LLP has filed a class action lawsuit against Verra Mobility Corp for securities fraud, contributing to lower after-market trading for the company.

31 июл. 2026 г., 23:26 UTC

News

Roblox Corp's stock is lower in after-market hours following UBS's price target cut to $45 and a class action lawsuit announcement by Pomerantz LLP.

31 июл. 2026 г., 23:16 UTC

News

KBR Inc. reported second-quarter revenue of $1.98 billion and reaffirmed full-year guidance, but shares are trading lower in after-market hours.

31 июл. 2026 г., 23:16 UTC

News

Tractor Supply Co reported second-quarter revenue of $4.54 billion, missing expectations. Shares are trading lower in after-market hours following the earnings release.

31 июл. 2026 г., 23:16 UTC

News

PBF Energy shares are lower in after-market hours following Citigroup's Neutral rating and price target increase to $74. The stock remains above its 20-day moving average.

31 июл. 2026 г., 23:16 UTC

News

Huntington Ingalls Industries shares rise in after-market trading following strong Q2 results, with sales of $3.42 billion and a non-GAAP profit of $5.27 per share.

31 июл. 2026 г., 23:16 UTC

News

Shares of GE Healthcare Technologies are lower in after-market trading following UBS's Neutral rating and a price target increase to $73.

31 июл. 2026 г., 23:16 UTC

News

Gilead Sciences shares are higher in after-market trading amid market fluctuations. Accessibility challenges for lenacapavir in Latin America may impact potential sales.

31 июл. 2026 г., 23:16 UTC

News

Alnylam Pharmaceuticals reported Q2 2026 net product revenue of $1.2 billion, driven by strong AMVUTTRA uptake. Shares rose slightly in after-market trading.

31 июл. 2026 г., 23:11 UTC

News

Lockheed Martin secured a $107.29 million Navy contract for VH-92A rotor blades, with shares trading higher in after-market hours.

31 июл. 2026 г., 23:06 UTC

News

Hawaiian Electric Industries has signed a 30-year power purchase agreement, with shares trading higher in after-market hours.

31 июл. 2026 г., 23:06 UTC

News

General Electric Co shares are lower in after-market trading, despite recent analyst upgrades and reaffirmed buy ratings for GE Aerospace.

31 июл. 2026 г., 23:06 UTC

News

Regeneron Pharmaceuticals shares declined in after-market hours following a class action lawsuit alleging securities fraud related to its Phase III study modifications.

31 июл. 2026 г., 23:06 UTC

News

Permian Resources Corp shares are trading higher in after-market hours following recognition as a top investment choice by Yahoo Finance, citing strong financial performance.

31 июл. 2026 г., 23:06 UTC

Social Media
News

NVIDIA shares are lower in after-market trading despite strong fiscal first-quarter results, with revenues of $81.6 billion and record data center sales.

31 июл. 2026 г., 23:06 UTC

News

Coinbase Global reported a record share of global crypto trading volume but also a significant net loss. Shares are roughly flat in after-market trading.

Сравнение c конкурентами

Изменение цены

Crinetics Pharmaceuticals Inc Прогноз

Целевая цена

By TipRanks

2.44% рост

Прогноз на 12 месяцев

Средняя 85.56 USD  2.44%

Максимум 95 USD

Минимум 80 USD

Основано на мнении 14 аналитиков Wall Street, спрогнозировавших целевые цены для Crinetics Pharmaceuticals Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Нейтрально

14 ratings

2

Покупка

12

Удержание

0

Продажа

Настроения

By Acuity

127 / 340Рейтинг в Здравоохранение

Новостные настроения

Свидетельства восходящего тренда

Волатильность

Ниже среднего

Объем новостей (RCV)

Ниже среднего

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
help-icon Live chat